Material Information- Regarding the 505(b)(2) new formulation drug HND-039 Omcazio patent infringement litigation has been voluntarily dismissed by the plaintiff
1.Parties to the legal matter:
Plaintiff：Exelixis, Inc
Defendant：Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC
2.Name of the court or punishing agency of the legal matter:United States District Court for DELAWARE
3.Reference/Case number of relevant documents of the legal matter:
NO. 1:26-cv-00813-UNA
4.Date of occurrence of the event:2026/08/28
5.Details of occurrence (including the matter under dispute):On July 7, 2026, Handa Pharmaceuticals, Inc., the subsidiary Handa Pharma, Inc. and Handa Oncology, LLC received a patent infringement notice from Exelixis, Inc. On August 28, 2026, plaintiff Exelixis, Inc. voluntarily dismissed this action without prejudice.
6.Handling procedure:The company has appointed legal counsel to handle the subsequent legal matters.
7.Impact on the Company’s finance and business and projected amount:There is no significant impact on the Company’s operations or financial condition.
8.Countermeasures and improvement status:The case has been referred to legal counsel, who will assist the Company in handling the subsequent legal matters.
9.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 2 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None